Fidasimtamab, also known as DLTV – 1504, represents a novel approach in the treatment against multiple myeloma. The drug is a bispecific molecule designed to concurrently engage CD3-positive lymphocytes https://fidasimtamabrawmaterial516716.blognody.com/53901747/fidasimtamab-a-promising-hope-in-advanced-myeloma-management